ArticleInfection and immunity2011
Vaccination with outer membrane complexes elicits rapid protective immunity to multidrug-resistant Acinetobacter baumannii.
Article in Infection and immunity, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Data-driven Atlas ofFrontiers in cellular and infection microbiology · 2026Pooled it
- Taming Superbugs: Current Progress and Challenges in Combating ESKAPE Pathogens.Pathogens (Basel, Switzerland) · 2025Review
- High-throughput single-cell analysis reveals Omp38-specific monoclonal antibodies that protect againstEmerging microbes & infections · 2025Article
- Identification and characterization of amphipathic antimicrobial peptides with broad spectrum activity against multi-drug resistant bacteria.Current research in microbial sciences · 2025Article
- Multidrug resistantCurrent research in microbial sciences · 2025Review
- Navigating ESKAPE Pathogens: Considerations and Caveats for Animal Infection Models Development.ACS infectious diseases · 2024Review
- Vitamins Can Increase Antibiotic Effects Against Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii in an In Vitro Infection Model.The Eurasian journal of medicine · 2024Article
- Investigation of Peptidoglycan-Associated Lipoprotein ofInfection and immunity · 2023Article
- Non-antibiotic prevention and treatment againstFrontiers in microbiology · 2023Review
- In Silico Analyses of Extracellular Proteins ofIranian journal of pharmaceutical research : IJPR · 2022Article
- Glycosphingolipids (GSLs) fromMolecules (Basel, Switzerland) · 2022Article
- Evaluation the reactivity of a peptide-based monoclonal antibody derived from OmpA with drug resistant pulsotypes of Acinetobacter baumannii as a potential therapeutic approach.Annals of clinical microbiology and antimicrobials · 2022Article
- Safety and Prophylactic Efficacy of Liposome-Based Vaccine against the Drug-ResistantPharmaceutics · 2022Article
- Review
- Safety and immunogenicity of a new glycoengineered vaccine against Acinetobacter baumannii in mice.Microbial biotechnology · 2022Article
- A Short Peptide of Autotransporter Ata Is a Promising Protective Antigen for Vaccination AgainstFrontiers in immunology · 2022Article
- CipA mediates complement resistance ofFrontiers in immunology · 2022Article
- Gold nanoparticle-DNA aptamer-assisted delivery of antimicrobial peptide effectively inhibits Acinetobacter baumannii infection in mice.Journal of microbiology (Seoul, Korea) · 2022Article
- Facing the challenges of multidrug-resistantHuman vaccines & immunotherapeutics · 2021Article
- Salmonella Typhimurium Adhesin OmpV Activates Host Immunity To Confer Protection against Systemic and Gastrointestinal Infection in Mice.Infection and immunity · 2021Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acinetobacter baumannii causes pneumonias, bacteremias, and skin and soft tissue infections, primarily in the hospitalized setting. The incidence of infections caused by A. baumannii has increased dramatically over the last 30 years, while at the same time the treatment of these infections has been complicated by the emergence of antibiotic-resistant strains. Despite these trends, no vaccines or antibody-based therapies have been developed for the prevention of A. baumannii infection. In this study, an outer membrane complex vaccine consisting of multiple surface antigens from the bacterial membrane of A. baumannii was developed and tested in a murine sepsis model. Immunization elicited humoral and cellular responses that were able to reduce postinfection bacterial loads, reduce postinfection proinflammatory cytokine levels in serum, and protect mice from infection with human clinical isolates of A. baumannii. A single administration of the vaccine was able to elicit protective immunity in as few as 6 days postimmunization. In addition, vaccine antiserum was used successfully to therapeutically rescue naïve mice with established infection. These results indicate that prophylactic vaccination and antibody-based therapies based on an outer membrane complex vaccine may be viable approaches to preventing the morbidity and mortality caused by this pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.